At the Fred Hutch-based HIV Vaccine Trials Network, researchers are testing out a new vaccine for the virus that causes AIDS that could help the body’s immune system produce “broadly neutralizing antibodies,” which are better equipped to block the many escape routes of this rapidly evolving virus.
As the need for protection against new COVID-19 variants increases, Fred Hutch researchers have developed a laboratory test to measure the effectiveness of new vaccines, speeding development of new variant-specific vaccines.
Through a series of incremental improvements on a gene therapy they developed nearly a decade ago, Fred Hutch researchers recently showed they had destroyed up to 95% of herpes virus lurking in certain nerve clusters in pre-clinical models, giving hope to people with this incurable virus.
The common Epstein-Barr virus is thought to be at least partly responsible for a handful of cancer types, mononucleosis and even multiple sclerosis. Fred Hutch scientists are testing a nanoparticle-based vaccine designed to train the immune system to attack unique proteins found on the virus’s surface.